Harvard Bioscience Inc. (HBIO) PT Raised to $7 at Benchmark, 'Q1 Beat & Raise; Outlook Improving; Raising Price Target'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Harvard Bioscience Inc. (HBIO) PT Raised to $7 at Benchmark, 'Q1 Beat & Raise; Outlook Improving; Raising Price Target'
April 25, 2023 8:01 AM EDT
Q1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior yearQ1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year
HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the first quarter ended March 31, 2023.
First quarter revenues were $30.0 million, up 4% versus $28.8 million in Q1 22. Reported revenue includes an unfavorable foreign exchange impact of... More
April 25, 2023 8:01 AM EDT
Q1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior yearQ1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year
HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the first quarter ended March 31, 2023.
First quarter revenues were $30.0 million, up 4% versus $28.8 million in Q1 22. Reported revenue includes an unfavorable foreign... More
